Nishikimi Toshio, Nakagawa Yasuaki
Department of Cardiovascular Medicine, Graduate School of Medicine Kyoto University, 54, Shogoin-Kawara-cho, Sakyo-ku, Kyoto 606-8507, Japan; Department of Medicine, Wakakusa-Tatsuma Rehabilitation Hospital, 1580 Tatsuma, Daito City, Osaka 574-0012, Japan.
Department of Cardiovascular Medicine, Graduate School of Medicine Kyoto University, 54, Shogoin-Kawara-cho, Sakyo-ku, Kyoto 606-8507, Japan.
Heart Fail Clin. 2018 Jan;14(1):49-55. doi: 10.1016/j.hfc.2017.08.006. Epub 2017 Oct 7.
Adrenomedullin (AM) is a vasodilatory peptide originally discovered in human pheochromocytoma tissue. Although AM is highly expressed in the adrenal glands, heart, lungs, and kidneys, vascular endothelium and smooth muscle are thought to be the main source of plasma AM. The AM precursor is processed to AM-glycine, which is then converted to AM-mature through C-terminal amidation. In this process, mid-regional pro-adrenomedullin (MR-proAM) is also produced. Plasma AM, AM-mature, AM-glycine, and MR-proAM levels are all higher in patients with heart failure than healthy subjects in proportional to the disease severity. All molecular forms of AM are prognostic markers for heart failure.
肾上腺髓质素(AM)是一种血管舒张肽,最初在人嗜铬细胞瘤组织中发现。尽管AM在肾上腺、心脏、肺和肾脏中高度表达,但血管内皮和平滑肌被认为是血浆AM的主要来源。AM前体被加工成AM-甘氨酸,然后通过C末端酰胺化转化为成熟的AM。在此过程中,还会产生中段前肾上腺髓质素(MR-proAM)。心力衰竭患者的血浆AM、成熟AM、AM-甘氨酸和MR-proAM水平均高于健康受试者,且与疾病严重程度成正比。AM的所有分子形式都是心力衰竭的预后标志物。